- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 7, 2025
Regulation
‘Arbitrary’ FDA decision-making puts U.S. innovation at risk, says Soon-Shiong
About-face by FDA on bladder cancer application stuns Immunitybio
BioCentury | Oct 31, 2024
Discovery & Translation
Science Spotlight: Macrophage-fibroblast cross-talk in heart failure
BioCentury’s roundup of translational innovations also includes synthetic gene regulators, three longevity genes and more
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | Jul 28, 2023
Emerging Company Profile
Genuv: multispecific cancer antibodies and neuroprotective small molecules
Seoul-based Genuv is developing a competitor to Roche’s anti-PD-1:IL-2 fusion for solid tumors; advancing a MEK inhibitor for neurodegeneration
BioCentury | Dec 8, 2022
Discovery & Translation
A mosaic nanoparticle vaccine for HCV; plus mitochondrial zinc finger base editors and more
BioCentury’s roundup of translational news
BioCentury | Jun 15, 2022
Data Byte
Third Rock’s penchant for platforms, product engines
The firm has backed 11 companies since the start of 2021; none are single-asset plays
BioCentury | Jun 14, 2022
Management Tracks
McCracken named CEO at Evonetix
Plus Pirzkall becomes CMO at Asher, and updates from Domain, Syndax,
BioCentury | Feb 7, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into cancer
BioCentury’s Distillery highlights white space cancer targets, new protein degraders and strategies to boost T cell responses to tumors
Items per page:
1 - 10 of 520